{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:22:26Z","timestamp":1790803346706,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institutes of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jpba.2014.11.011","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T21:27:01Z","timestamp":1416346021000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC\/MS\/MS"],"prefix":"10.1016","volume":"104","author":[{"given":"Lee C.","family":"Winchester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Podany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney V.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2014.11.011_bib0100","unstructured":"2013. World Health Organization (WHO) Global tuberculosis report 2013."},{"key":"10.1016\/j.jpba.2014.11.011_bib0010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am. J. Respiratory Critic. Care Med."},{"key":"10.1016\/j.jpba.2014.11.011_bib0105","unstructured":"2010. Stop TB Initiative. Treatment of tuberculosis: guidelines. World Health Organization."},{"key":"10.1016\/j.jpba.2014.11.011_bib0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2014.11.011_bib0025","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/BF00615223","article-title":"Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects","volume":"34","author":"Perucca","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2014.11.011_bib0030","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1128\/AAC.43.5.1230","article-title":"Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study","volume":"43","author":"Keung","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2014.11.011_bib0035","first-page":"1650","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis Infection","volume":"60","author":"Jereb","year":"2011","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.jpba.2014.11.011_bib0040","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2014.11.011_bib0045","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/cit246","article-title":"Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study","volume":"57","author":"Luetkemeyer","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2014.11.011_bib0050","unstructured":"U.S. Food and Drug Administration (FDA) Guidance for Industry, Bioanalytical Methods Validation, http:\/\/www.fda.gov\/cder\/guidance\/4252fnl.htm, 2001."},{"key":"10.1016\/j.jpba.2014.11.011_bib0055","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2014.11.011_bib0060","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1208\/s12248-009-9100-9","article-title":"Workshop report and follow-up \u2014 AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples \u2014 implications of Crystal City recommendations","volume":"11","author":"Fast","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.jpba.2014.11.011_bib0065","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.4155\/bio.09.108","article-title":"Incurred sample reproducibility: views and recommendations by the European Bioanalysis Forum","volume":"1","author":"Timmerman","year":"2009","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2014.11.011_bib0070","first-page":"522","article-title":"Quantification of ethambutol, isoniazid, pyrazinamide, rifabutin and rifampicin in serum using LC\u2013MS\/MS","volume":"33","author":"Mueller","year":"2011","journal-title":"Therap. Drug Monit."},{"key":"10.1016\/j.jpba.2014.11.011_bib0075","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jpba.2009.11.001","article-title":"Rifampicin determination in plasma by stir bar-sorptive extraction and liquid chromatography","volume":"51","author":"Balb\u00e3o","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2014.11.011_bib0080","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jpba.2011.07.041","article-title":"Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma","volume":"56","author":"Fox","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2014.11.011_bib0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchromb.2007.07.005","article-title":"A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin","volume":"857","author":"Hartkoorn","year":"2007","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2014.11.011_bib0090","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jpba.2012.05.028","article-title":"Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographic\u2013tandem mass spectrometric method","volume":"70","author":"Srivastava","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2014.11.011_bib0095","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00007691-199712000-00011","article-title":"Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies","volume":"19","author":"Le Guellec","year":"1997","journal-title":"Ther. Drug Monit."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851400538X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851400538X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T14:57:39Z","timestamp":1566053859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170851400538X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":19,"alternative-id":["S073170851400538X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2014.11.011","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC\/MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2014.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}